GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing
multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, today announced that the company plans to participate in
two upcoming investor conferences.
GenMark’s management is scheduled to present at the William Blair 40th Annual Growth Stock Conference in a virtual setting on Wednesday, June 10th, 2020 at 12:20 a.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.
GenMark’s management team will also be hosting virtual one-on-one meetings at the Raymond James Human Health Innovations Conference on Tuesday, June 16, 2020. Interested parties can contact their representative at Raymond James for additional information.
GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor detection technology, GenMark's eSensor XT-8 and ePlex systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
GenMark Diagnostics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de